Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Quest PharmaTech Inc.
ClinicalTrials.gov Identifier:
NCT01616303
First received: May 30, 2012
Last updated: September 29, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2018
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)